A lawsuit in Philadelphia involves claims against the makers of popular weight loss drugs like Ozempic and Wegovy. Patients experienced gastrointestinal issues after taking these medications and allege that the companies did not adequately warn them about the risks. These drugs belong to the GLP-1 agonist class and were originally approved for Type 2 diabetes treatment. The lawsuit raises concerns about the safety of weight loss drugs, implicating public trust and potential impacts on the market. Despite FDA approval, rising sales, and positive scientific studies, the lawsuit highlights the importance of understanding the risks associated with these medications.
Source link
Lawsuit could challenge trust in Ozempic and other popular weight loss drugs
